Arthroscopy 32(3):495505 Dragoo JL, Wasterlain AS, Braun HJ, Nead KT (2014) Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial
No needles, no downtimejust transformative results that fit seamlessly into your lifestyle
Safety through selectivity: Peptides' targeted mechanisms explain excellent safety profiles
Because robust human safety data are limited, it is difficult to give a definitive side-effect profile with meaningful incidence rates
Pre-clinical rodent models of tendon rupture have shown combined BPC-157 and TB-500 protocols to produce faster return of tensile strength and superior histological organisation compared to either single-peptide treatment or untreated controls
It occurs in human plasma, saliva and urine, and its levels decline with age [1] [2]